| Ticker | BBIO |
|---|---|
| ISIN | US10806X1028 |
| Sector | Atención sanitaria |
| Mercado | NASDAQ |
BridgeBio Pharma, Inc. engages in the discovery, development, and delivery of various medicines for genetic diseases. The company has a pipeline of 30 development programs that include product candidates ranging from early discovery to late-stage development. Its products in development programs include AG10 and BBP-265, a small molecule stabilizer of transthyretin, or TTR that is in Phase 3 clinical trial for the treatment of TTR amyloidosis-cardiomyopathy, or ATTR-CM; BBP-831, a small molec...
BridgeBio Pharma, Inc. opera en el sector Healthcare, industria Biotechnology.